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Abstract
Promising phase II clinical results have been reported recently for several oncolytic viral therapeutics, including strains
based on vaccinia virus. One reason for this has been an increased appreciation of the critical therapeutic importance
of the immune response raised by these viruses. However, the most commonly used approaches to enhance these
immunotherapeutic effects in oncolytic viruses, typically though expression of cytokine transgenes, often also result
in a reduction in oncolytic activity and premature clearance of the virotherapy from the tumor. Approaches that
enhance the immunotherapeutic effects while maintaining oncolytic activity would therefore be beneficial. Here, it
is demonstrated that the expression of the chemokine CCL19 (ELC) from an oncolytic vaccinia virus (vvCCL19) results
in increased antitumor effects in syngeneic mouse tumor models. This corresponded with increased T cell and
dendritic cell infiltration into the tumor. However, vvCCL19 persisted in the tumor at equivalent levels to a control virus
without CCL19, demonstrating that oncolytic activity was not curtailed. Instead, vvCCL19 was cleared rapidly and
selectively from normal tissues and organs, indicating a potentially increased safety profile. The therapeutic activity
of vvCCL19 could be further significantly increased through combinationwith adoptive transfer of therapeutic immune
cells expressing CCR7, the receptor for CCL19. This approach therefore represents ameans to increase the safety and
therapeutic benefit of oncolytic viruses, used alone or in combination with immune cell therapies.
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Introduction
There has been a resurgence of interest in oncolytic viral cancer ther-
apies due to the exciting phase II clinical results reported with several
different viral vectors [1–3] and the entry of these into randomized
testing [4]. However, despite reports of therapeutic responses, complete
responses remain elusive and approaches that enhance the activity of
these vectors are still needed.
One factor driving the advances in this next generation of
oncolytic viruses has been the realization that their immunothera-
peutic activity is critical for their success [5,6]. However, this is a
double-edged sword, as most approaches that increase the immuno-
therapeutic activity of the oncolytic vectors also result in reduced
oncolytic activity and early immune-mediated clearance of the agents
from the tumor. In particular, although expression of cytokines from
oncolytic viruses frequently results in increased antitumor effects, a
closer examination reveals that this increased overall activity comes
despite a significant loss of viral replicative capacity within the tumor
[7]. It is therefore apparent that approaches that enhance the inter-
actions of oncolytic viruses with the immune response while main-
taining oncolytic activity would result in the greatest therapeutic
benefits. As such, the effects of chemokine expression from the viral
vectors were explored. It was hypothesized that chemokine expres-
sion may simultaneously help overcome one of the major limitations
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of immunotherapy, an inability of effector cells to efficiently traffic to
the tumor, while also leading to a more subtle targeting of the im-
mune response, with less direct immune activation than seen with
commonly used cytokine transgenes. In addition, chemokine expres-
sion may lead to synergistic combinations with immune cell therapies
expressing the appropriate receptors.
We have previously reported on a strain of vaccinia virus expres-
sing the chemokine CCL5 (RANTES) [8]. This strain (vvCCL5) dis-
played some unexpected properties, including the capacity to persist
for extended periods in the tumors of mouse models of cancer. Here,
the effects of expression of the chemokine CCL19 from an oncolytic
vaccinia strain were examined. Whereas the receptors for CCL5
(CCR1, CCR3, and CCR5) are known to attract a wide range of im-
mune cells, including immature dendritic cells (DCs) and Th1 and
Th2 T cells to sites of inflammation, the lymph node targeting receptor
for CCL19 (CCR7) is expressed on a more restricted set of immune
cells, including mature DCs and T cells [9]. CCL19 was chosen for
two reasons, first, to interact directly with cytokine induced killer
(CIK) cells (that express the cognate receptor CCR7) and, second, to
attract DCs and naïve T cells into the tumor in the context of viral
infection and the associated transient overcoming of immune suppres-
sion, as this may enhance the previously demonstrated in situ vaccina-
tion effect produced by oncolytic vaccinia strains.
Initial in vivo testing in mouse tumor models determined that
CCL19 expression enhanced therapeutic effects but had no signifi-
cant effect on the level or persistence of the virus in the tumor and
instead led to more rapid clearance of the virus from elsewhere within
the host. The mechanisms behind this enhanced safety and the en-
hanced antitumor effects of oncolytic vaccinia expressing CCL19
used alone or in combination with adoptive immune cell therapy
are examined.
Materials and Methods
Cell Lines and Viruses
MC38 murine colon adenocarcinoma cell line was originally in-
duced with oral dimethylhydrazine in C57BL/6 mice and has been
used extensively by ourselves and others. 6780 Cells were a kind gift
from Dr Dean Felsher (Stanford University); these cells are a primary
lymphoma cell line isolated from a transgenic mouse model of spon-
taneous lymphoma. The CV-1 cell line used for plaque assay was pur-
chased from ATCC (Manassas, VA).
All recombinant vaccinia strains were in a Western Reserve back-
ground. The vaccinia virus double-deleted (vvDD) strain, a viral
thymidine kinase and vaccinia growth factor double deletion, has
been reported previously [10]. vvCCL19 (a version of vvDD
expressing mCCL19 from the p7.5 promoter) was constructed for
this work (Figure W1).
In Vitro Viral Replication Assay
MC38 cells infected at multiplicity of infection (MOI) of 0.1 were
harvested at indicated times, subjected to three cycles of freeze-thaw,
and the cell lysate was homogenized with a FastPrep Cell Disrupter
(Model FP120; Qbiogene, Inc, Carlsbad, CA) to release virions. Virus
was then titered by standard plaque assay on CV-1 cells.
Enzyme-Linked Immunosorbent Assay
MC38 cells were infected with either vvCCL19 or vvDD at an
MOI = 1.0. Twenty-four hours later, supernatants were collected
and run on ELISA assay for detection of CCL19 production with
DuoSet ELISA Development Kit (R&D Systems, Minneapolis, MN)
according to the manufacturer’s guidelines.
Immune Cell Preparation
Activated NKT (CIK) cells were expanded from spleens of Luc+
Tg FVB mice as previously described [11]. Briefly, splenocytes were
cultured with interferon-gamma (IFN-γ) and anti-CD3e antibody for
24 hours, before being cultured for 10 to 15 days with interleukin-2
(IL-2) added. Bulk splenocytes represent whole-spleen populations
after RBC lysis only.
In Vitro Transwell Chemotaxis Assay
Supernatant was added into the lower wells of 3.0-μm pore-size
96-well Transwell (Corning, NY) plates, while 50,000 immune cells
were added into each of the upper wells. These were incubated at 37°C
for 3 hours, and the numbers of migrated immune cells were counted
by flow cytometry.
Mouse Models
Female FVB and C57BL/6 mice were obtained from Taconic
(Germantown, NY) at 6 weeks old. All animal studies were approved by
theUniversity of Pittsburgh Institutional Animal Care andUse Committee.
For biodistribution, Luminex, and immunohistochemistry assays,
C57BL/6 mice were injected subcutaneously with 200,000 MC38
cells. When the tumors reached 50 to 100 mm3, animals were treated
with intraperitoneal (IP) or intravenous (IV) injection of phosphate-
buffered saline (PBS), virus, or immune cells as indicated. For viral
biodistribution, mice were sacrificed, tissues were frozen and homog-
enized, and the viral plaque forming units recovered were titered; for
immune cell biodistribution, cells expressing luciferase were analyzed
by bioluminescence imaging on an IVIS200 (Xenogen, part of Caliper
Life Sciences) after injection with luciferin (Caliper Life Sciences, Perkin
Elmer,Waltham,MA) and anesthesia with 2% isoflurane; for flow cytom-
etry, tumors were harvested and dissociated with enzyme lysis buffer; for
immunohistochemistry, tissues were harvested and frozen for subsequent
sectioning and staining; for Luminex array assays, tissues were collected,
weighed, and ground in PBS buffer; BCA protein assays were performed,
and the samples were normalized. For tumor response assays, tumor sizes
were measured every other day by caliper measurement.
Ex Vivo Assays
Antibodies used in flow cytometry included labeled anti-CD4, anti-
CD8, anti-NK1.1, and anti-CD11c (BD Pharmingen, San Jose, CA)
with Mouse Regulatory T cell Staining Kit (eBioscience, San Diego, CA);
samples were analyzed on a Beckman Coulter XL32 EXPO or a DAKO
Cyan flow cytometer.
Immunohistochemistry and immunofluorescence sections were incu-
bated with anti-CD4 or CD8 followed by appropriate secondary antibodies
(eBioscience). Epifluorescence images were taken using an Olympus Provis
lightmicroscope (Olympus America, Center Valley, PA), andMetaMorph
(Molecular Devices, Downington, PA) was used for image analysis.
Luminex array assays were performed with Milipore Mouse 32-Plex
in the University of Pittsburgh Cancer Institute facility and were nor-
malized to the level of overall protein in samples after homogenization
and lysis of the tumor samples.
Statistical Methods
Unpaired and paired Student’s t tests were used to determine statis-
tical significance (defined as P < .05).
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Results
vvCCL19 Selectively Attracts Lymphocytes Expressing
CCR7 In Vitro
The oncolytic vaccinia strain vvDD has been studied extensively in
preclinical models and is currently undergoing phase I clinical testing.
This vector contains tumor-targeting deletions in the viral thymidine
kinase and viral growth factor genes [10,12]. A version of vvDD was
constructed for this work expressing murine CCL19 under control of
the pSE/L promoter and expressed from within the thymidine kinase
locus, vvCCL19 (Figure W1). This virus was confirmed to secrete
CCL19 after infection of MC38 (mouse colorectal tumor) cells in vitro
and viral replication was found to be unaffected by CCL19 expression
(Figure W1).
Expression profiles for CCR7 (the receptor for CCL19) were exam-
ined on both a naïve splenocyte population and activated natural killer
(NK)–T cell therapeutic cells (CIK cells [11,13]). It was confirmed that
whereas CCR7 was expressed at very low levels on the bulk splenocyte
population, CCR7 was expressed on a significant subset (approximately
25%) of the CIK cells (Figure 1A). It is unclear why CCR7 is expressed
on CIK cells, as these represent an activated T cell population that would
not normally be expected to express this receptor. This was reflected in
the capacity for the CIK cells to traffic to media collected from infected
MC38 cells in an in vitro chemotaxis assay (Figure 1B). Only the CIK
cells trafficked in significant numbers and only to media from vvCCL19-
infected cells. This confirmed that vvCCL19 produced functionally
active CCL19 that was capable of attracting cells expressing CCR7.
It is also notable that vvDD apparently reduced trafficking of CIK cells
(although not significantly); this may be indicative of expression of viral
virulence genes known to block the action of chemokines.
vvCCL19 Displayed Enhanced Antitumor Effect In Vivo
Mice (C57/BL6) were implanted with subcutaneous MC38 tumors,
and when these became palpable (50–100 mm3), they were treated via IP
injection with 1 × 108 plaque forming units (PFU) of vvDD or vvCCL19.
It was confirmed that CCL19 was expressed in the tumor only after
vvCCL19 therapy (Figure 1C ). Subsequent caliper measurements of
tumor growth determined that vvCCL19 displayed significantly greater
therapeutic benefit than vvDD (Figure 1D). This therapeutic benefit
was seen despite the fact vvDD and vvCCL19 replicated to identical levels
in the same MC38 cell line in vitro (Figure W1), implying that CCL19
expression is likely mediating an immune response that enhances the
antitumor effects in vivo. It is notable that vvDD and vvCCL19 both pro-
duced significant therapeutic benefit relative to PBS controls over the first
7 to 10 days after treatment, but that only vvCCL19 treatment was
capable of extending these significantly enhanced therapeutic effects (rel-
ative to vvDD) from day 14 onward. However, despite these significantly
enhanced therapeutic effects no complete responses were produced.
vvCCL19 Selectively Attracts DCs and CD4+ T Cells
into the Tumor
To explore the hypothesis that an altered immune response may
be mediating the increased therapeutic benefit seen with vvCCL19,
Figure 1. (A) CCR7 is expressed on CIK cells but not on bulk splenocytes. Populations of bulk inactivated mouse splenocytes and CIK
cells were labeled with anti-CCL19 antibody and analyzed by flow cytometry. The percentage of cells positive for CCL19 (above an
isotype control) is shown, average of three independent experiments (P < .001). (B) vvCCL19-infected MC38 cells secrete functional
CCL19. Media from MC38 tumor cells infected with vvDD or vvCCL19 or mock infected for 24 hours (MOI = 1.0) were collected and
filter sterilized before levels of CIK attraction were determined in a chemotaxis assay. Results are average of three experiments (*P< .01;
note that vvDD shows a trend toward reduced attraction of CIK cells, but this is not significant; P =.06). (C) Systemic treatment with
vvCCL19 leads to increased CCL19 levels in the tumors. Mice (C57/BL6 bearing MC38 subcutaneous tumors, n = 3 per group) were
treated via IP injection with indicated viruses (1 × 108 PFU/mouse) and the levels of CCL19 were determined in recovered tumors by
ELISA after 3 days (P< .05). (D) Mice (C57/BL6 bearingMC38 subcutaneous tumors, n= 8 per group) were treated as before, subsequent
tumor volume was determined by caliper measurement. vvCCL19 treatment was significantly better (P< .05) than other treatments from
day 14 onward.
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MC38 tumors were recovered from mice at different times after
treatment with PBS, vvDD, or vvCCL19. Tumor sections were
then stained with antibodies to CD11c, CD4, and CD8, while
tumors were also dissociated into single-cell suspensions before
staining with different antibodies (Figure 2A) and quantification
of tumor-infiltrating cell types by flow cytometry. It was de-
termined (Figure 2) that both CD4+ and CD11c+ cell populations
were significantly increased in tumors from mice treated with
vvCCL19 relative to any other treatment but not until 8 days after
treatment (at a similar time to when the therapeutic advantage of
vvCCL19 over vvDD also appears to become significant; Figure 1D
and 2B). The level of CD8+ T cells in the tumor did not show any
significant differences until even later after initial treatment, with
increased levels appearing after vvCCL19 treatment (relative to
vvDD) at day 12 only (Figure 2C ). This is in line with the delayed
induction of an immune response at later times after viral therapy.
Other cell types, including NK cells displayed no significant differ-
ences between vvDD- and vvCCL19-treated animals at any time.
Further, the CD4+ cells selectively attracted to the vvCCL19-treated
tumors did not represent regulatory T cells, as there were no differ-
ences in the levels of CD4+Foxp3+ cells in the tumors with or with-
out vvCCL19 treatment (Figure 2C ). Treatment with vvCCL19
therefore appeared to enhance the infiltration of immune cells into
the tumor but not until later times after treatment.
vvCCL19 Is Cleared Selectively from Nontumor Tissues
but Persists in the Tumor
Previously, an oncolytic vaccinia strain expressing the chemokine
CCL5 was found to display increased persistence within the tumor after
IV delivery [8], while no significant differences were seen in viral load in
any other organs. The levels of virus within different tissues were there-
fore examined after treatment of MC38 tumor–bearing mice with
vvDD or vvCCL19. In contrast to vvCCL5, vvCCL19 did not dis-
play any significant differences in the viral load within the tumor at
any times after systemic delivery relative to vvDD (Figure 3), meaning
that CCL19 expression did not result in premature clearance from the
tumor, like that seen with expression of many cytokines, or extended
persistence like vvCCL5. However, it was noted that vvCCL19 was
instead more rapidly cleared selectively from nontumor tissues, with
no detectable virus recovered from brain, ovary, liver, or spleen as soon
as 4 days after systemic delivery. The tumor was the only tissue from
which vvCCL19 could be recovered at this point. In contrast, vvDD
was still detectable in multiple nontumor tissues at this time. It there-
fore appears that expression of CCL19 may confer a safety benefit on
oncolytic vaccinia strains, whereas tumor replication of vvCCL19 was
apparently unaffected by the increased influx of DCs and CD4+ T cells
(presumably as the increased immune cell infiltration did not become
significant until 8 days after treatment, at which point virus is being
cleared from the tumor anyway).
Figure 2. Immune effects of CCL19 expression. (A) Sections from MC38 tumors treated systemically with the indicated viruses and
recovered at the indicated time points (days after treatment). Sections were stained with anti-CD11c antibody (red), anti-CD4+ antibody
(green), and 4′6-diamidino-2-phenylindole (DAPI) (nuclei) (original magnification, ×200). (B) Tumors recovered as before were also dis-
sociated into single-cell suspensions and stained with either anti-CD4 antibody or anti-CD11c. Percentages of different immune infil-
trates were then determined by flow cytometry (n = 4 per group). At day 8, vvCCL19-treated tumors contained significantly more
CD3+CD4+ (P = .003) and CD11c+ (P = .017) cells. (C) Samples from day 8 were also stained for regulatory T cells (CD4+FoxP3+) and
CD3+CD8+ T cells; neither showed any difference between groups.
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Increased Cytokine Production in Nontumor Tissues Correlates
with Rapid Clearance of vvCCL19
Luminex assay was used to determine the level of different cyto-
kines within the spleen and the tumor at different times after systemic
treatment with vvDD or vvCCL19 (Figure 4). It was noted that
several cytokines, including IL-12, IFN-γ, and tumor necrosis factor
alpha (TNF-α), and IL-1, and several chemokines, including CXCL9
(Mig), CCL2 (MCP-1), and CXCL10 (IP-10), were increased in the
spleens from vvCCL19-treated animals relative to vvDD treatment
within 4 days of treatment, while minimal differences were observed
in the levels of any cytokines in the tumor at this time after treatment
with either virus. It therefore appears that CCL19 expression selectively
enhances immune activation in nontumor tissues at the earlier time
points. Enhanced cytokine production was seen in the tumors of
vvCCL19-treated animals at 8 days after treatment however (relative
to vvDD treatment), again indicating that the increased immuno-
therapeutic effect is delayed within the tumor microenvironment and
supporting the observation of enhanced immune cell infiltration only
at the later times (Figure 2).
Combining vvCCL19 with CIK Cell Therapy Significantly
Enhances Therapeutic Benefit
Because vvCCL19 is capable of selectively attracting CIK cells in cul-
ture (Figure 1B), it was hypothesized that a combination of vvCCL19
and CIK therapy would represent a potent combination in vivo. In ini-
tial experiments, mice were implanted with bilateral tumors, with one
flank tumor receiving vvCCL19 via direct intratumoral injection and
vvDD injected into the tumor on the opposite flank. IV delivery of
CIK cells expressing luciferase combined with bioluminescence imag-
ing determined that the CIK cells trafficked to the tumor treated with
virus expressing CCL19 in significantly greater numbers (Figure 5A).
In this experiment, the tumor model was switched to the lymphoma
cell line 6780 implanted into FVB mice to take advantage of FVB-
Luc transgenic mice for expansion of the CIK cells and also to extend
the system into a second model.
Furthermore, a comparison of treatment with vvDD (IP) fol-
lowed by CIK therapy (IV) 3 days later relative to equivalent treat-
ment with vvCCL19 followed by CIK therapy again determined a
greater infiltration of CIK cells into the tumor in combination with
vvCCL19 (Figure 5B) and a very significant benefit for the use of
Figure 4. Cytokine production in spleen and tumor after treatment
with vvDD or vvCCL19. Mice (C57/BL6 bearing subcutaneousMC38
tumors, n = 5 per group) were treated systemically (IP) with 1 ×
108 PFU of the indicated viruses. Mice were sacrificed after 4 and
8 days, and tumor and spleens were recovered for analysis of cyto-
kine production by Luminex assay. Many cytokines are increased
in the tumor after vvCCL19 production (relative to vvDD) at day 4,
whereas there is little difference in the tumor until day 8.
Figure 3. Biodistribution and persistence of different viruses after treatment in tumor-bearing mice. C57/BL6 mice bearing subcutaneous
MC38 tumors as before were again treated with 1 × 108 PFU of vvDD or vvCCL19 and sacrificed at the indicated times after treatment
(n = 3 per group per time). The indicated organs were recovered and tissues were homogenized. Viral titers were determined by plaque
assay and normalized to the concentration of protein in the samples.
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CCL19-expressing virus (Figure 5C ). vvCCL19 therefore con-
fers a therapeutic advantage both when used alone and when
used in combination with adoptive immune cell transfer therapies
expressing CCR7.
Discussion
Despite the promising clinical data reported with different oncolytic
vaccinia strains, further advances to increase safety, specificity, and effi-
cacy are still needed before regular complete responses are seen. One
area that has gained much attention recently has involved approaches
that enhance the immunotherapeutic potential of the viruses. This is
most commonly achieved through expression of cytokines as transgenes
from the viral vectors, and both the herpes simplex virus (HSV) and
vaccinia oncolytic strains currently undergoing randomized clinical
testing express the cytokine granulocyte macrophage-colony stimulat-
ing factor (GM-CSF) [4]. Other strains expressing cytokines including
IFN [14] and TNF [7] have also displayed promising results in a pre-
clinical setting. However, it is notable that although cytokine expres-
sion frequently increases the overall therapeutic effects of the viral vectors,
this often comes at the cost of reduced oncolytic activity, with less viral
replication within the tumor and earlier immune-mediated clearance of
the therapy [7]. In addition, although cytokine expression can increase
the safety of the viral vectors (through rapid clearance from nontumor
tissues) [14], there have also been reports of toxicity resulting from sys-
temic cytokine release, with some systemic cytokine expression from
oncolytic viruses resulting in acute toxicity early after IV delivery
(Thorne, in press, Molecular Therapy 2012).
As an alternative but complimentary approach, we have explored the
effects of expressing chemokines from the oncolytic viruses. Because
chemokines act to direct trafficking of immune cells, they have the po-
tential to overcome one of the major limitations of immunotherapy of
cancer, an inability to target effector cells into the tumor. Further, because
chemokines primarily direct rather than activate the immune response,
their effects will likely be more subtle, meaning that their expression
may not act to directly inhibit viral replication and oncolytic effects and
may result in improved safety. We previously reported on an oncolytic
vaccinia virus expressing the chemokine CCL5 [8] that displayed an un-
expected capacity to persist within the tumor for extended periods of time.
It was therefore decided to investigate the therapeutic potential of
expression of the chemokine CCL19, whose interaction with its cog-
nate receptor (CCR7) is more typically associated with recirculation of
mature DCs and T cells into lymph nodes. The receptor for CCL19
(CCR7) is also expressed on many immune cell therapies (including
CIK cells) and on T cells produced as a result of vaccination [15,16],
meaning that it is likely to synergize with these immunotherapy
approaches. Vaccinia oncolytic strain vvDD was therefore constructed
expressing murine CCL19 (vvCCL19). Initial testing confirmed that
functional CCL19 was secreted from infected cells and that this
attracted cells expressing CCR7. In addition, CCL19 expression did
not affect viral replication in vitro. It was also determined that CCL19
expression was sufficient to impart a therapeutic advantage on the
oncolytic virus when applied in a mouse tumor model.
Analysis of the effects of CCL19 expression on immune cell infil-
trate into the tumor and on viral persistence and biodistribution con-
firmed key differences in the use of chemokine expression relative to
what is typically seen with most cytokine expression; CCL19 expres-
sion both enhanced the immunotherapeutic effects and the safety of
the vector, yet did not result in a reduction in viral oncolytic potential.
In particular, CCL19 expression resulted in increased infiltration of a
variety of immune cells into the tumor, including DC and CD4+ and
CD8+ T cells (but not NK cells). However, CCL19 expression did not
result in increased viral persistence in the tumor or premature viral clear-
ance from the tumor; instead, virus was selectively cleared more rapidly
from nontumor tissues (including spleen, brain, and ovary). It therefore
Figure 5. (A) Adoptively transferred immune cells preferentially
traffic to tumors treated with vaccinia expressing CCL19. Mice
(FVB bearing bilateral subcutaneous 6780 tumors on either flank,
n = 5) received virus (1 × 108 PFU) via intratumoral injection, with
vvDD on one flank and vvCCL19 on the opposite flank 24 hours
after injection with CIK cells expressing luciferase (expanded from
a transgenic luciferase expressing mouse) via tail vein injection.
Subsequent trafficking of CIK cells to each flank tumor was quan-
tified at times after injection by bioluminescence imaging (P < .05
at 72 and 120 hours). (B) vvCCL19 preferentially attracts CIK cells
into the tumor. Mice (C57/BL6) with subcutaneous MC38 tumors
received IP injection of vvDD or vvCCL19 (1 × 108 PFU, n = 8 per
group), followed by 1 × 108 CIK cells prelabeled with cell tracker
72 hours later. After a further 72 hours, mice were sacrifice and
tumors were recovered and dissociated, and the percentage of
transferred CIK cells in the tumor was determined by flow cytome-
try (P > .01). (C) vvCCL19 in combination with CIK cells displayed
enhanced therapeutic benefit. Mice (C57/BL6) with subcutaneous
MC38 tumors received IP injection of vvDD or vvCCL19 (1 × 108
PFU, n = 8 per group), followed by 1 × 108 CIK cells or PBS
72 hours later. Antitumor effect was followed by caliper measure-
ment (P < .05 at all times after day 10 for vvCCL19 and CIK group
compared to all other groups.)
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appears that CCL19 expression may 1) act to increase immunotherapeu-
tic effects without decreasing oncolytic activity and 2) may enhance the
safety of the viral therapy through rapid clearance from nontumor tissues.
However, further investigation is still needed, as other factors in addition
to the increased immune infiltrate maymediate the enhanced therapeutic
effects. In addition, at the doses tested, vvCCL19 displayed only a slight
but not significant benefit in reducing weight loss (a surrogate marker for
viral pathogenicity) after treatment relative to vvDD (data not shown).
It is likely however that more significant safety benefits would be seen
at higher doses, meaning that it may be possible to apply vvCCL19 at
higher doses in the clinic without encountering toxicity in other organs.
Although insignificant differences in immune cell infiltrate and
cytokine levels in the tumors of vvCCL19-treated animals were seen
as soon as 4 days after treatment (compared to vvDD-treated animals),
large and significant differences were not seen in the tumor until 8 days
after the treatments. This is also the last time point at which virus
(vvDD or vvCCL19) was detected in the tumor environment. It there-
fore appears that the immunotherapeutic effects of CCL19 expression
are not significantly felt in the tumor until around 8 days after treat-
ment. This also coincided with the time at which vvCCL19 began to
demonstrate significant therapeutic advantages over vvDD. This raises
the possibility that over an initial “oncolytic phase” (the first 8 days after
treatment), vvDD and vvCCL19 act in a similar way within the tumor.
However, by 8 days after treatment, when the viral therapies are being
cleared, CCL19 expression acts to enhance the immune infiltrate arriving
within the tumor and so imparts an immunotherapeutic advantage on the
mice treated with vvCCL19 that continues after the virus has been cleared.
In contrast to the situation in the tumor, in the spleen many cyto-
kines were increased within 4 days of treatment with vvCCL19 relative
to vvDD. This correlated with the more rapid clearance of vvCCL19
from nontumor tissues at this time. It therefore appears that vvCCL19
may be capable of inducing a more rapid immune response in non-
tumor tissues, leading to its early clearance from these organs, while
the immune response in the tumor may be delayed.
It is unclear why the effects of CCL19 expression are not felt in the
tumor until 8 days after treatment (whereas they are clear by 4 days in
other organs), but this may be indicative of the immune suppressive
microenvironment in the tumor, meaning that either longer term or
higher expression is needed for effect or that the first cells attracted
into the tumor become subverted and that other adjuvant immune
signals (such as those released after viral lysis of infected cells) are
needed before immune activation is achieved.
It is also of note that after 8 days both vvDD and vvCL19 are
cleared from the tumor, meaning that the period of oncolytic activity
is limited. However, the additional immune activation of vvCCL19
may allow for long-term immune activation and targeting of tumor
antigens, so allowing an ongoing therapeutic benefit. Although several
strategies have been incorporated to increase the period of active viral
replication in the tumor, these typically involve immune suppression
and have little overall therapeutic benefit.
Although significant, the therapeutic advantage of vvCCL19 is not
dramatic relative to vvDD. However, another advantage of chemo-
kine expression from oncolytic viral therapies is the potential for
synergy during combination treatment with vaccine or immune cell
therapies. This was explored through combination with a model of
adoptive T cell therapy, using CIK cells. CIK cells were found to
express the CCR7 receptor on at least a subset of the population
and displayed increased trafficking to vvCCL19-infected tumor cells
both in vitro and in vivo. Further, when vvCCL19 was used in com-
bination with CIK cells in mouse colorectal cancer models, it pro-
duced a far more significant and durable therapeutic response
(relative to treatment with a vvDD and CIK combination).
It therefore appears that CCL19 expression from an oncolytic vac-
cinia vector imparts multiple advantages, including enhanced safety
(more rapid clearance from nontumor tissues), enhanced immuno-
therapeutic effect (increased immune infiltration into the tumor), and
maintenance of oncolytic activity (no premature clearance of the virus),
as well as the capacity to synergize with immune cell or vaccine-based
therapies. This resulted in enhanced therapeutic benefit, both for virus
used alone and particularly when used in combination with adoptive
transfer of CCR7 expressing therapeutic immune cells. These promising
preclinical data warrant clinical testing of this vector.
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Figure W1. (A) Diagram displaying construction of vvCCL19 (TKR, thymidine kinase right-hand region; TKL, thymidine kinase left-hand
region; VGF, vaccinia growth factor; pSE/L, synthetic early/late promoter; p7.5 E/L, 7.5 promoter early/late). (B) Production of CCL19
under different conditions (detected by ELISA in media 24 hours after infection of MC38 cell layer at MOI of 1.0). (C) Replication of vvDD
and vvCCL19 in MC38 cells as determined by plaque assay on CV-1 cells (MOI of 1.0).
